Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out

C. Proto, R. Ferrara, D. Signorelli, G. Lo Russo, G. Galli, M. Imbimbo, A. Prelaj, N. Zilembo, M. Ganzinelli, L. M. Pallavicini, I. De Simone, M. P. Colombo, A. Sica, V. Torri, M. C. Garassino

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and platinum-based chemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamous and non-squamous NSCLC without oncogenic drivers. Furthermore, double immune checkpoint inhibition has shown promising results in treatment naïve patients with high tumor mutational burden (TMB). Of note, the presence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the best treatment option may still be platinum-based chemotherapy. To date, first-line single agent immune checkpoint blockade has demonstrated limited activity in EGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns in both EGFR and ALK positive NSCLC patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumab in combination with platinum-based chemotherapy and bevacizumab is emerging as a potential treatment option upon progression to first line tyrosine kinase inhibitors.

Original languageEnglish
Pages (from-to)39-51
Number of pages13
JournalCancer Treatment Reviews
Volume75
DOIs
Publication statusPublished - May 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Platinum
Tumor Burden
Drug Therapy
Therapeutics
Protein-Tyrosine Kinases
Safety
Neoplasms

Keywords

  • Chemotherapy
  • First line treatment
  • Immunotherapy
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC) : what to add and what to leave out. / Proto, C.; Ferrara, R.; Signorelli, D.; Lo Russo, G.; Galli, G.; Imbimbo, M.; Prelaj, A.; Zilembo, N.; Ganzinelli, M.; Pallavicini, L. M.; De Simone, I.; Colombo, M. P.; Sica, A.; Torri, V.; Garassino, M. C.

In: Cancer Treatment Reviews, Vol. 75, 05.2019, p. 39-51.

Research output: Contribution to journalReview article

Proto, C. ; Ferrara, R. ; Signorelli, D. ; Lo Russo, G. ; Galli, G. ; Imbimbo, M. ; Prelaj, A. ; Zilembo, N. ; Ganzinelli, M. ; Pallavicini, L. M. ; De Simone, I. ; Colombo, M. P. ; Sica, A. ; Torri, V. ; Garassino, M. C. / Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC) : what to add and what to leave out. In: Cancer Treatment Reviews. 2019 ; Vol. 75. pp. 39-51.
@article{3e6b1aeb3e7c4426adbe681a107573b8,
title = "Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out",
abstract = "Immunotherapy has dramatically changed the therapeutic scenario in treatment na{\"i}ve advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50{\%}, the combination of pembrolizumab or atezolizumab and platinum-based chemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamous and non-squamous NSCLC without oncogenic drivers. Furthermore, double immune checkpoint inhibition has shown promising results in treatment na{\"i}ve patients with high tumor mutational burden (TMB). Of note, the presence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the best treatment option may still be platinum-based chemotherapy. To date, first-line single agent immune checkpoint blockade has demonstrated limited activity in EGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns in both EGFR and ALK positive NSCLC patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumab in combination with platinum-based chemotherapy and bevacizumab is emerging as a potential treatment option upon progression to first line tyrosine kinase inhibitors.",
keywords = "Chemotherapy, First line treatment, Immunotherapy, NSCLC",
author = "C. Proto and R. Ferrara and D. Signorelli and {Lo Russo}, G. and G. Galli and M. Imbimbo and A. Prelaj and N. Zilembo and M. Ganzinelli and Pallavicini, {L. M.} and {De Simone}, I. and Colombo, {M. P.} and A. Sica and V. Torri and Garassino, {M. C.}",
year = "2019",
month = "5",
doi = "10.1016/j.ctrv.2019.03.004",
language = "English",
volume = "75",
pages = "39--51",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC)

T2 - what to add and what to leave out

AU - Proto, C.

AU - Ferrara, R.

AU - Signorelli, D.

AU - Lo Russo, G.

AU - Galli, G.

AU - Imbimbo, M.

AU - Prelaj, A.

AU - Zilembo, N.

AU - Ganzinelli, M.

AU - Pallavicini, L. M.

AU - De Simone, I.

AU - Colombo, M. P.

AU - Sica, A.

AU - Torri, V.

AU - Garassino, M. C.

PY - 2019/5

Y1 - 2019/5

N2 - Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and platinum-based chemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamous and non-squamous NSCLC without oncogenic drivers. Furthermore, double immune checkpoint inhibition has shown promising results in treatment naïve patients with high tumor mutational burden (TMB). Of note, the presence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the best treatment option may still be platinum-based chemotherapy. To date, first-line single agent immune checkpoint blockade has demonstrated limited activity in EGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns in both EGFR and ALK positive NSCLC patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumab in combination with platinum-based chemotherapy and bevacizumab is emerging as a potential treatment option upon progression to first line tyrosine kinase inhibitors.

AB - Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and platinum-based chemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamous and non-squamous NSCLC without oncogenic drivers. Furthermore, double immune checkpoint inhibition has shown promising results in treatment naïve patients with high tumor mutational burden (TMB). Of note, the presence of both negative PD-L1 expression and low TMB may identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the best treatment option may still be platinum-based chemotherapy. To date, first-line single agent immune checkpoint blockade has demonstrated limited activity in EGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns in both EGFR and ALK positive NSCLC patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumab in combination with platinum-based chemotherapy and bevacizumab is emerging as a potential treatment option upon progression to first line tyrosine kinase inhibitors.

KW - Chemotherapy

KW - First line treatment

KW - Immunotherapy

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=85063918357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063918357&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2019.03.004

DO - 10.1016/j.ctrv.2019.03.004

M3 - Review article

C2 - 30954906

AN - SCOPUS:85063918357

VL - 75

SP - 39

EP - 51

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -